Overview

Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia

Status:
Withdrawn

Trial end date:
2017-01-01

Target enrollment:

Participant gender:

Summary

Determination of the maximum tolerated dose (MTD) of fractionated RIT with epratuzumab radiolabeled with yttrium-90 (90Y-epratuzumab) preceding a reduced conditioning regimen FB2A2 before allogeneic stem cell transplantation.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Nantes University Hospital

Collaborators:

Gilead Sciences
Immunomedics, Inc.
Institut Cancerologie de l'Ouest

Treatments:

Busulfan
Epratuzumab
Fludarabine
Thymoglobulin